» Articles » PMID: 33532619

Cardiovascular and Renal Effectiveness of Empagliflozin in Routine Care in East Asia: Results from the EMPRISE East Asia Study

Abstract

Aim: To evaluate the effectiveness of empagliflozin in clinical practice in East Asia in the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) East Asia study.

Materials And Methods: Data were obtained from the Medical Data Vision database (Japan), National Health Insurance Service database (South Korea) and National Health Insurance database (Taiwan). Patients aged ≥ 18 years with type 2 diabetes initiating empagliflozin or a dipeptidyl peptidase-4 (DPP-4) inhibitor were 1:1 propensity score (PS) matched into sequentially built cohorts of new users naïve to both drug classes. This design reduces confounding due to switching treatments, time lag and immortal time biases. Outcomes included hospitalization for heart failure (HHF), end-stage renal disease (ESRD) and all-cause mortality. Hazard ratios (HRs) and 95% CIs were estimated using Cox proportional models, controlling for > 130 baseline characteristics in each data source and pooled by random-effects meta-analysis.

Results: Overall, 28 712 pairs of PS-matched patients were identified with mean follow-up of 5.7-6.8 months. Compared with DPP-4 inhibitors, the risk of HHF was reduced by 18% and all-cause mortality was reduced by 36% with empagliflozin (HR 0.82; 95% CI 0.71-0.94, and HR 0.64; 95% CI 0.50-0.81, respectively). Reductions were consistent across countries, and in patients with and without baseline cardiovascular disease. ESRD was also significantly reduced with empagliflozin versus DPP-4 inhibitors (HR 0.37; 95% CI 0.24-0.58).

Conclusions: Empagliflozin treatment was associated with reduced risk for HHF, all-cause mortality and ESRD compared with DPP-4 inhibitors in routine clinical practice in Japan, South Korea and Taiwan.

Citing Articles

The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.

Aranishi T, Igarashi A, Hara K, Osumili B, Cai Z, Mizogaki A Diabetes Ther. 2024; 16(3):431-445.

PMID: 39708085 PMC: 11868005. DOI: 10.1007/s13300-024-01675-7.


Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes in Patients with Acute Coronary Syndrome and Type 2 Diabetes.

Xie H, Jiang M Diabetes Metab Syndr Obes. 2024; 17:4377-4386.

PMID: 39600926 PMC: 11591705. DOI: 10.2147/DMSO.S459368.


Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative....

Langslet G, Nystrom T, Vistisen D, Carstensen B, Grip E, Casajust P J Diabetes Res. 2024; 2024:6142211.

PMID: 39430801 PMC: 11490347. DOI: 10.1155/2024/6142211.


Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus.

Jeon J, Kim D Diabetes Metab J. 2024; 48(5):837-846.

PMID: 39313229 PMC: 11449826. DOI: 10.4093/dmj.2024.0317.


Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes.

Suzuki Y, Kaneko H, Okada A, Komuro J, Ko T, Fujiu K Nephrol Dial Transplant. 2024; 40(3):495-504.

PMID: 38991990 PMC: 11879043. DOI: 10.1093/ndt/gfae158.


References
1.
Kadowaki T, Nangaku M, Hantel S, Okamura T, von Eynatten M, Wanner C . Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME trial. J Diabetes Investig. 2018; 10(3):760-770. PMC: 6497612. DOI: 10.1111/jdi.12971. View

2.
Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

3.
Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

4.
Kosiborod M, Cavender M, Fu A, Wilding J, Khunti K, Holl R . Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose.... Circulation. 2017; 136(3):249-259. PMC: 5515629. DOI: 10.1161/CIRCULATIONAHA.117.029190. View

5.
Kaku K, Lee J, Mattheus M, Kaspers S, George J, Woerle H . Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME. Circ J. 2016; 81(2):227-234. DOI: 10.1253/circj.CJ-16-1148. View